Analysis of the antitumoral mechanisms of lipopolysaccharide against glioblastoma multiforme

Anti-Cancer Drugs

Volumn 14, Issue 6, 2003, Pages 457-466

  Won, Eun Kyung ^a   Zahner, Michael C ^a   Grant, Elizabeth A ^a   Gore, Pankaj ^a   Chicoine, Michael R ^a,b  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dexamethasone; Glioblastoma multiforme; Lipid A; Lipopolysaccharide; Nude mouse; SCID mouse

Indexed keywords

DEXAMETHASONE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; LIPID A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER REGRESSION; CANCER SURVIVAL; CANCER TRANSPLANTATION; CONTROLLED STUDY; DOSE RESPONSE; GLIOBLASTOMA; IMMUNOCOMPETENCE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SCID MOUSE; SINGLE DRUG DOSE; T LYMPHOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BRAIN NEOPLASMS; DEXAMETHASONE; DRUG INTERACTIONS; FEMALE; GLIOBLASTOMA; LIPID A; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; SPECIES SPECIFICITY;

EID: 0042126772     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200307000-00012     Document Type: Article

References (47)

1. Burton EC, Prados MD. Malignant gliomas. Curr Treat Options Oncol 2000; 1:459-468.
2. Croteau D, Mikkelsen T. Adults with newly diagnosed high-grade gliomas. Curr Treat Options Oncol 2001; 2:507-515.
3. Levin VA. Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: the past decade and where we are heading. Neuro-oncology 1999; 1:69-80.
4. Chicoine MR, Won EK, Zahner M. Intratumoral injection of lipopolysaccharide causes regression of s.c. implanted mouse DBT glioblastoma multiforme. Neurosurgery 2001; 48:607-615.
5. Ben-Nathan D, Padgett DA, Loria RM. Androstendiol and dehydroepiandrosterone protect mice against lethal bacterial infections and lipopolysaccharide toxicity. J Med Microbiol 1999; 48:425-431.
6. Davenpeck KL, Zagorski J, Schleimer RP, Bochner BS. Lipopolysaccharide-induced leukocyte rolling and adhesion in the mesenteric microcirculation: regulation by glucocorticoids and role of cytokines. J Immunol 1998; 161:6861-6870.
7. Fukuma K, Marubayashi S, Okada K, Yamada K, Kimura A, Dohi K. Effect of Lazaroid U-74389G and methylprednisolone on endotoxin-induced shock in mice. Surgery 1999; 125:421-430.
8. Han SJ, Choi JH, Ko HM, Yang HW, Choi IW, Lee HK, et al. Glucocorticoids prevent NF-kappaB activation by inhibiting the early release of platelet-activating factor in response to lipopolysaccharide. Eur J Immunol 1999; 29:1334-1341.
9. Messmer UK, Winkel G, Briner VA, Pfeilschifter J. Glucorticoids potently block tumor necrosis factor-alpha and lipopolysaccharide-induced apoptotic cell death in bovine glomerular endothelial cells upstream of caspase 3 activation. Br J Pharmacol 1999; 127:1633-1640.
10. Qiu HB, Pan JQ, Du B, Zhao YQ, Chen DC. Effects of dexamethasone, ibuprofen, and ligustrazini on lipopolysaccharides-induced tumor necrosis factor alpha production. Chung Kuo Yao Lo Hsueh Pao 1997; 18:67-70.
11. Akimoto T, Kumazawa E, Jimbo T, Joto N, Tohgo A. Antitumor effect of DT-5461a, a synthetic low-toxicity Lipid A analog, involves endogenous tumor necrosis factor induction subsequent to macrophage activation. Int J Immunopharmacol 1994; 16:887-893.
12. Akimoto T, Kumazawa E. Jimbo T, Joto N, Tohgo A. DT-5461a, an antitumor synthetic lipid A analog causes selective blood flow reduction in tumor tissue. Anticancer Res 1995; 15:105-107.
13. Kumazawa E, Akimoto T, Kita Y. Intratumoral production of tumor necrosis factor augmented by endogenous interferons results in potent antituumor effects of DT-5461, a synthetic lipid A analog. J Immunother 1995; 17:141-150.
14. Sato K, Yoo YC, Mochizuki M, Saiki I, Takahashi TA, Azuma I. Inhibition of tumor-induced angiogenesis by a synthetic lipid A analogue with low endotoxicity, DT-5461. Jpn J Cancer Res 1995; 86:374-382.
15. Sato K, Yoo YC, Fukushima A, Saiki I, Takashi TA, Fujihara M, et al. A novel synthetic lipid A analog with low endotoxicity, DT-5461, prevents lethal endotoxemia. Infect Immun 1995; 63:2859-2866.
16. Vosika GJ, Barr C, Gilbertson D. Phase I study of intravenous modified lipid A. Cancer Immunol Immunother 1984; 18:107-112.
17. Freedman HH, Sultzer BA, Kleinberg W. Detoxification of bacterial endotoxin with retention of ability to stimulate non-specific resistance to infection. Proc Soc Exp Biol Med 1961; 136:819-823.
18. Nowotny A, Golub S, Brian K. Fate and effect of endotoxin derivatives in tumor-bearing mice. Proc Soc Exp Biol Med 1971; 136:66-69.
19. Engelhardt R, Mackensen A, Galanos C, Andreesen R. Biological response to intravenously administered endotoxin in patients with advanced cancer. J Biol Response Mod 1990; 9:480-491.
20. Engelhardt R, Otto F., Mackensen A, Mertelsmann R, Galanos C. Endotoxin (Salmonella abortus equi) in cancer patients. Clinical and immunological findings. Prog Clin Biol Res 1995; 392:253-261.
21. Goto S, Sakai S, Kera J, Suma Y, Soma GI, Takeuchi S, Intradermal administration of lipopolysaccharide in treatment of human cancer. Cancer Immunol Immunother 1996; 42:255-261.
22. Mackensen A, Galanos C, Engelhardt R. Treatment of cancer patients with endotoxin induces release of endogenous cytokines. Pathobiology 1991; 59:264-267.
23. Old LJ. Tumor necrosis factor. Sci Am 1988; 258:59-75.
24. Otto F, Schmid P, Mackesen A, Wehr U, Seiz A, Braun M, et al. Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur J Cancer 1996; 32A:1712-1718.
25. Bowles AP, Perkins E. Long-term remission of malignant brain tumors after intracranial infection: a report of four cases. Neurosurgery 1999; 44:636-643.
26. Akimoto T, Kumazawa E, Jimbo T, Joto N, Tohgo A. DT-5461a, an antitumor synthetic lipid A analog causes selective blood flow reduction in tumor tissue. Anticancer Res 1995; 15:105-107.
27. Chicoine MR, Silbergeld DL. Assessment of brain tumor cell motility in vivo and in vitro. J Neurosurg 1995; 82:615-622.
28. Chicoine MR, Madsen CL, Silbergeld DL. Modification of human glioma cell locomotion in vitro by cytokines: EGF, bFGF, PDGFbb, NGF, and TNFα Neurosurgery 1995; 36:1165-1171.
29. Chicoine MR, Silbergeld DL. The in vitro motility of human gliomas increases with increasing grade of malignancy. Cancer 1995; 75:2904-2909.
30. Chicoine MR, Silbergeld DL. Invading C6 glioma cells maintain tumorigenicity. J Neurosurg 1995; 83:665-671.
31. Hansen EW, Malling D, Christensen JD. Endotoxin-stimulated release of cytokines by cultured cells from the murine neurohypophysis: role of dexamethasone and indomethacin. Neuroimmunomodulation 1999; 6:330-335.
32. Hattori Y, Murakami Y, Atsuta H, Minamino N, Kangawa K, Kasai K. Glucorticoid regulation of adrenomedullin in a rat model of endotoxic shock. Life Sci 1998; 62:PL181-189.
33. Pistritto G, Franzese O, Pozzoli G, Mancuso C, Tringali G, Preziosi P, et al. Bacterial lipopolysaccharide increases prostaglandin production by rat astrocytes via inducible cyclo-oxygenase: evidence for the involvement of nuclear factor kappa B. Biochem Biophys Res Commun 1999; 263:570-574
34. Zentay Z, Sharaf M, Qadir M, Drafta D, Davidson D. Mechanism for dexamethasone inhibition of neutrophil migration upon exposure to lipopolysaccharide in vitro: role of neutrophil interleukin-8 release. Pediatr Res 1999; 46:406-410.
35. Yethon JA, Heinrichs DE, Monteiro MA, Perry MB, Whitfield C. Involvement of waaY, waaQ, and waaP in the modification of Escherichia coli lipopolysaccharide and their role in the formation of a stable outer membrane. J Biol Chem 1998; 273:263110-263116.
36. Giavazzi R, Garofalo A, Damia G, Garattini S, D'Incalci M. Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts. Br J Cancer 1988; 57:277-280.
37. Maeda YY, Hamuro J, Chihara G. Mechanisms of action of antitumor polysaccharides. I. The effect of antilymphocyte serum on the antitumor activity of lentinan. Int J Cancer 1971; 8:41-46.
38. Maeda YY, Chihara G. The effects of neonatal thymectomy on the anti-tumor activity of lentinan, carboxymethylpachymaran and zymosan, and their effects on various immune responses. Int J Cancer 1973; 11:153-156.
39. Saito M, Ichimura O, Kataoka M, et al. Pronounced antitumor effect of LAK-like cells induced in the peritoneal cavity of mice after intraperitoneal injection of OK-432, a killed streptococcal preparation. Cancer Immunol Immunother 1986; 22:161-168.
40. Corbel C, Melchers F. Requirement for macrophages or for macrophage- or T cell-derived factors in the mitogenic stimulation of murine B lymphocytes by lipopolysaccharides. Eur J Immunol 1983; 13:528-533.
41. Qureshi ST, Gros P, Malo D. The Lps locus: genetic regulation of host responses to bacterial lipopolysaccharide. Inflamm Res 1999; 48:613-620.
42. Wong PMC, Chung SW, Sultzer BM. Genes, receptors, signals and response to lipopolysaccharide endotoxin. Scand J Immunol 2000; 51:123-127.
43. Farias-Eisner R, Sherman M, Aeberhard E, Chaudhuri G. Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci USA 1994; 91:9407-9411.
44. Castro AG, Neighbors M, Hurst SD, Zonin F, Silva RA, Murphy E, et al. Anti-interleukin 10 receptor monoclonal antibody is an adjuvant for T helper cell type 1 responses to soluble antigen only in the presence of lipopolysaccharide. J Exp Med 2000; 192:1529-1534.
45. h1 phenotype. Blood 1997; 90:1920-1926.
46. Allison AC. Immunological adjuvants and their modes of action. Arch Immunol Ther Exp (Warsz) 1997; 45:141-147.
47. Yokochi T, Kato Y, Sugiyama T, Koide N, Norikawa A, Jiang GZ, et al. Lipopolysaccharide induces apoptotic cell death of B memory cells and regulates B cell memory in antigen-nonspecific manner. FEMS Immunol Med Microbiol 1996; 15:1-8.